Reviva Pharmaceuticals
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10080 N Wolfe Rd Ste SW3200, Cupertino, ...Phone Number
(408) 501-8881Website
www.revivapharma.comRevenue
$41.7 MillionStock Symbol
RVPHIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Reviva Pharmaceuticals
Reviva Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on discovering and developing novel therapies for central nervous system, respiratory, and metabolic diseases. Its lead drug candidate, brilaroxazine (RP5063), is in clinical development for multiple unmet neuropsychiatric indications including schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychotic symptoms in Alzheimers disease, Parkinsons disease psychosis, and attention deficit hyperactivity disorder (ADHD). The company is headquartered in Cupertino, California.Explore more
Reviva Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Reviva Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Reviva Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Reviva Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when Reviva Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Reviva Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Reviva Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Reviva Pharmaceuticals
Click to see if Reviva Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Reviva Pharmaceuticals has new funding data
Recommended Actions
Reach out to Masked Content who joined Reviva Pharmaceuticals as Masked Content
Find 3 more new buyers
Compare Similar Companies to Reviva Pharmaceuticals
Compare insights from companies similar to Reviva Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Reviva Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Reviva Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Reviva Pharmaceuticals.
Reviva Pharmaceuticals financials insights
Gather financial insights about Reviva Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Private Equity
$15.8M
2016
Debt
$1.2M
2017
Angel/Seed
$4.8M
2024
Stock Offering
$18M
Reviva Pharmaceuticals Tech Stack
A closer look at the technologies used by Reviva Pharmaceuticals
Most Recent Scoops
Project
Reviva Pharmaceuticals has reported that brilaroxazine demonstrated significantly lower treatment discontinuation rates compared to approved antipsychotics, with 12% to 16% discontinuation in Phase II and Phase III 4-week trials versus 30% to 42% historically, and 36% dropout over one year of treatment compared to 60% to 80% in historical data.
Pharmaceuticals
Project
Reviva Pharmaceuticals has successfully completed a Phase III clinical trial for brilaroxazine in schizophrenia, consisting of a double-blind study in 411 patients across two doses (15 mg and 50 mg) compared to placebo, followed by a one-year long-term extension enrolling approximately 450 additional patients to evaluate efficacy, safety, and compliance.
Clinical Operations
Project
Reviva Pharmaceuticals has reported a favorable safety profile for brilaroxazine across more than 900 patients treated, with motor side effects occurring in less than 1% of patients, minimal weight gain, no drug-induced liver injury, no clinically meaningful cardiac side effects, and normalization of prolactin levels within four weeks of treatment.
Medical Research, Pharmaceuticals
Project
Reviva Pharmaceuticals has reported that brilaroxazine achieved a statistically significant 10-point separation from placebo on the primary endpoint (PANSS) in its Phase III trial, with early onset of action observed in the first week, representing approximately 30% to over 50% greater efficacy than widely used antipsychotics based on historical comparisons.
Project
Pharmaceuticals
Reviva Pharmaceuticals News & Media
Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase
CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form of brilaroxazine in the RECOVER-2 trial and future NDA expected in mid-2026 - - Initiation of patient enrollment in RECOVER-2 registrational Phase 3 trial expected Q3 2026 -Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications
CUPERTINO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat hosted by A.G.P. Equity Research Analyst JamesRVPH: Shareholder Letter Introduces New IP - Zacks Small Cap Research
By John Vandermosten, CFA NASDAQ: RVPH On behalf of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), Chief Executive Officer, Dr. Laxminarayan Bhat, composed a letter to shareholders acknowledging the difficult path over the last year. The missive justified the capital raises over the last 10 months, citing the priorities of strengthening the balance sheet, supporting operations to achieve
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Reviva Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Reviva Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on discovering and developing novel therapies for central nervous system, respiratory, and metabolic diseases. Its lead drug candidate, brilaroxazine (RP5063), is in clinical development for multiple unmet neuropsychiatric indications including schizophrenia, bipol... Read More
